熊去氧胆酸治疗对非裔美国人原发性胆汁性胆管炎总生存的改善更显著
基于Fibrotic Liver Disease Consortium数据,纳入4238例原发性胆汁性胆管炎患者,采用逆概率治疗加权和Cox回归分析,发现未治疗的非裔美国人和亚裔/美洲印第安人/太平洋岛民死亡率高于白人,而治疗逆转此关联;熊去氧胆酸降低所有组肝移植/死亡风险,非裔美国人治疗与死亡率显著降低相关。
要点
- 非裔美国人未治疗时死亡率高于白人,治疗与死亡率显著降低相关
- 熊去氧胆酸降低所有患者组肝移植/死亡风险
- 基线胆红素即使正常范围内偏高也增加死亡和肝移植风险
核心结论
- 非裔美国人和亚裔/美洲印第安人/太平洋岛民未治疗时死亡率高于白人,治疗逆转该关联
- 非裔美国人治疗与死亡率显著降低相关
- 无论是否治疗,基线胆红素高于低正常水平与死亡和肝移植/死亡风险增加相关
研究设计与样本
- 纳入4238例原发性胆汁性胆管炎患者(13%男性;8%非裔美国人,7%亚裔/美洲印第安人/太平洋岛民;21%西班牙裔),78%曾接受熊去氧胆酸
- 采用逆概率治疗加权调整治疗选择偏倚,Cox回归评估治疗与 mortality 及肝移植/死亡的关联
主要发现
- 未治疗患者中,非裔美国人和亚裔/美洲印第安人/太平洋岛民死亡率高于白人(aHR=1.34,95%CI 1.08-1.67;aHR=1.40,95%CI 1.11-1.76)
- 治疗患者中,非裔美国人和亚裔/美洲印第安人/太平洋岛民与白人死亡率关联逆转(aHR=0.67,95%CI 0.51-0.86;aHR=0.88,95%CI 0.67-1.16)
- 熊去氧胆酸降低所有患者组肝移植/死亡风险,并降低除白人女性且AST/ALT≥1.1外所有组的死亡率
- 与基线低正常胆红素(≤0.4 mg/dL)相比,高正常(1.0>0.7)和中正常(0.7>0.4)胆红素患者肝移植/死亡和全因死亡率显著更高
关键数值与推荐
- 未治疗非裔美国人死亡率aHR=1.34(95%CI 1.08-1.67),亚裔/美洲印第安人/太平洋岛民aHR=1.40(95%CI 1.11-1.76)
- 治疗非裔美国人死亡率aHR=0.67(95%CI 0.51-0.86),亚裔/美洲印第安人/太平洋岛民aHR=0.88(95%CI 0.67-1.16)
- 基线胆红素分层:低正常≤0.4 mg/dL,中正常0.7>0.4 mg/dL,高正常1.0>0.7 mg/dL
临床怎么用
- 对原发性胆汁性胆管炎患者应关注种族差异,非裔美国人未治疗时死亡风险更高
- 熊去氧胆酸治疗可降低非裔美国人死亡率,支持在该人群中积极治疗
- 基线胆红素即使正常范围偏高也应视为风险增加标志
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We used data from the Fibrotic Liver Disease Consortium to evaluate the impact of ursodeoxycholic acid (UDCA) treatment across race/ethnicity, gender, and clinical status among patients with primary biliary cholangitis. METHODS: Data were collected from "index date" (baseline) through December 31, 2016. Inverse Probability of Treatment Weighting was used to adjust for UDCA treatment selection bias. Cox regression, focusing on UDCA-by-risk factor interactions, was used to assess the association between treatment and mortality and liver transplant/death. RESULTS: Among 4,238 patients with primary biliary cholangitis (13% men; 8% African American, 7% Asian American/American Indian/Pacific Island [ASINPI]; 21% Hispanic), 78% had ever received UDCA. The final multivariable model for mortality retained age, household income, comorbidity score, total bilirubin, albumin, alkaline phosphatase, and interactions of UDCA with race, gender, and aspartate aminotransferase/alanine aminotransferase ≥1.1. Among untreated patients, African Americans and ASINPIs had higher mortality than whites (adjusted hazard ratio [aHR] = 1.34, 95% confidence interval [CI] 1.08-1.67 and aHR = 1.40, 95% CI 1.11-1.76, respectively). Among treated patients, this relationship was reversed (aHR = 0.67, 95% CI 0.51-0.86 and aHR = 0.88, 95% CI 0.67-1.16). Patterns were similar for liver transplant/death. UDCA reduced the risk of liver transplant/death in all patient groups and mortality across all groups except white women with aspartate aminotransferase/alanine aminotransferase ≥1.1. As compared to patients with low-normal bilirubin at baseline (≤0.4 mg/dL), those with high-normal (1.0 > 0.7) and mid-normal bilirubin (0.7 > 0.4) had significantly higher liver transplant/death and all-cause mortality. DISCUSSION: African American and ASINPI patients who did not receive UDCA had significantly higher mortality than white patients. Among African Americans, treatment was associated with significantly lower mortality. Regardless of UDCA treatment, higher baseline bilirubin, even within the normal range, was associated with increased mortality and liver transplant/death compared with low-normal levels.
引用
- Gordon SC, Wu KH, Lindor K, et al. Ursodeoxycholic Acid Treatment Preferentially Improves Overall Survival Among African Americans With Primary Biliary Cholangitis. Am J Gastroenterol. 2020. PMID: 31985529. doi:10.14309/ajg.0000000000000512
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。